Search Results

Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications, launch a new assay for quantifying pharmacodynamic markers of radioligand therapies in tumors.

Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications announces the launch of its new multiplex spatial biology assay services for rapid, whole-slide imaging and analysis of tissue sections at subcellular resolution.

Navigate BioPharma Services, Inc. in Collaboration with Partners Validate Analytical Assay for Acute Myeloid Leukemia Measurable Residual Disease (AML-MRD) Assessment.

As they navigate a competitive job market, biopharma professionals are making four key interview mistakes, according to two talent acquisition experts. They discuss those errors and offer tips for how to get those critical conversations right.

Biopharma employees reporting a positive business outlook for their companies dropped month over month but increased year over year in February, according to the Glassdoor Employee Confidence Index. Glassdoor’s findings align with recent BioSpace data.

Navigate BioPharma Services, Inc. announces a strategic collaboration with BD (Becton, Dickinson and Company) to explore opportunities to develop and commercialize flow cytometry-based companion diagnostics and tools for clinical decisions.

Over 80% of those living outside of biopharma’s biggest hubs, like San Diego or Boston, have a tough time finding work, according to a BioSpace LinkedIn poll. Biopharma professionals in Oregon and Connecticut and a BioSpace recruitment manager share their insights on this issue.

After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.